Back to Stakeholders
Research, Drug Development & ManufacturingLead program: Phase I

Algernon PharmaceuticalsCSE: AGN

Also known as: Algernon Health, Algernon NeuroScience

1 Drug Candidate1 Trial

Algernon Pharmaceuticals (also known as Algernon Health / Algernon NeuroScience) is the first company in the world to test DMT as an emergent treatment for ischemic stroke and traumatic brain injury. Their lead candidate AP-188 uses sub-hallucinogenic IV DMT to promote neuroplasticity and neuroprotection. Phase 1 completed at the Centre for Human Drug Research in Leiden; Phase 2a stroke trial planned.

Drug Pipeline

1

AP-188

DMT
Phase I
Neurological InjuryTraumatic Brain Injury (TBI)

Sub-hallucinogenic IV DMT (6-hr infusion) for neuroprotection and neuroplasticity post-stroke and TBI. Phase 1 completed (Netherlands, CHDR). Phase 2a stroke trial planned for Hungary.

Quick Facts

Type
Public Biotech
Ticker
CSE: AGN
Lead Stage
Phase I
Website
Visit

Sponsored Trials

1
Active not recruitingI

Single and Repeat Doses of DMT in Healthy Subjects

Start Date
Compounds
DMT, Placebo